TRPC6 and liver dysplastic nodule: In conclusion, the results of our experiment suggest that FK506 protects podocytes in DN by decreasing apoptosis, alleviating proteinuria, and delaying the progression of renal function deterioration; these effects may be mediated by decreased TRPC6 expression, perhaps providing new concepts for the use of FK506 as a DN therapy.